Genitourinary Cancers Sympsium

Preliminary Evidence Shows Increase in Higher-Risk Prostate Cancers Between 2011 and 2013

A new study that analyzed data from more than 87,500 men with prostate cancer shows that the number diagnosed with higher-risk disease increased between 2011 and 2013. According to these results, the number of men diagnosed with either intermediate- or high-risk disease has increased by nearly 6% since 2011. These findings are interesting because in 2011 the U.S. Preventive Services Task Force (USPSTF) recommended that PSA testing not be used for prostate cancer screening, regardless of a man’s age.

No Benefit Seen With Targeted Therapy After Surgery for Locally Advanced Kidney Cancer

A recent study suggests that people with locally advanced kidney cancer should not take either sorafenib (Nexavar) or sunitinib (Sutent) after surgery. Sorafenib and sunitinib are two drugs that are widely used to treat kidney cancer that has spread to other parts of the body. They target the process of angiogenesis, blocking the growth of new blood vessels to the tumor. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumor.

Blood Test May Help Predict Most Effective Treatment for Castration-Resistant Prostate Cancer in the Future

For many types of cancer, doctors are able to run laboratory tests to identify specific genes, proteins, and other factors unique to the tumor that help determine the best treatment option for each patient. However, there are currently no tests to help doctors select the best treatment option for men with metastatic castration-resistant prostate cancer (mCRPC).

Active Surveillance for Intermediate-Risk Prostate Cancer Linked With Decreased Survival

A new study that analyzed data from 945 men with prostate cancer raises questions about recommending active surveillance to men with intermediate-risk disease. Compared to men with low-risk prostate cancer, those with intermediate-risk disease had a nearly four-times higher chance of dying from prostate cancer within 15 years when their disease was managed using active surveillance.


Subscribe to RSS - Genitourinary Cancers Sympsium